130 related articles for article (PubMed ID: 21030263)
1. 1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists.
Choi J; Park Y; Lee HS; Yang Y; Yoon S
Bioorg Med Chem; 2010 Dec; 18(23):8315-23. PubMed ID: 21030263
[TBL] [Abstract][Full Text] [Related]
2. Identification of (beta-carboxyethyl)-rhodanine derivatives exhibiting peroxisome proliferator-activated receptor gamma activity.
Choi J; Ko Y; Lee HS; Park YS; Yang Y; Yoon S
Eur J Med Chem; 2010 Jan; 45(1):193-202. PubMed ID: 19879669
[TBL] [Abstract][Full Text] [Related]
3. Selective, potent PPARgamma agonists with cyclopentenone core structure.
Otero MP; Pérez Santín E; Rodríguez-Barrios F; Vaz B; de Lera AR
Bioorg Med Chem Lett; 2009 Apr; 19(7):1883-6. PubMed ID: 19275963
[TBL] [Abstract][Full Text] [Related]
4. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
Lu IL; Huang CF; Peng YH; Lin YT; Hsieh HP; Chen CT; Lien TW; Lee HJ; Mahindroo N; Prakash E; Yueh A; Chen HY; Goparaju CM; Chen X; Liao CC; Chao YS; Hsu JT; Wu SY
J Med Chem; 2006 May; 49(9):2703-12. PubMed ID: 16640330
[TBL] [Abstract][Full Text] [Related]
5. Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.
Nevin DK; Peters MB; Carta G; Fayne D; Lloyd DG
J Med Chem; 2012 Jun; 55(11):4978-89. PubMed ID: 22582973
[TBL] [Abstract][Full Text] [Related]
6. [Design, synthesis, and PPARalpha/gamma agonistic activity of novel tetrahydroisoquinoline derivatives].
Yu R; Zhou YL; Huan Y; Liu Q; Shen ZF; Liu ZZ
Yao Xue Xue Bao; 2011 Mar; 46(3):311-6. PubMed ID: 21626786
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of dihydropyrano-[2,3-c]pyrazoles as a new class of PPARγ partial agonists.
Qvortrup K; Jensen JF; Sørensen MS; Kouskoumvekaki I; Petersen RK; Taboureau O; Kristiansen K; Nielsen TE
PLoS One; 2017; 12(2):e0162642. PubMed ID: 28245241
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and structure-activity relationships of pyrazole derivatives as potential FabH inhibitors.
Lv PC; Sun J; Luo Y; Yang Y; Zhu HL
Bioorg Med Chem Lett; 2010 Aug; 20(15):4657-60. PubMed ID: 20594840
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists.
Peng YH; Coumar MS; Leou JS; Wu JS; Shiao HY; Lin CH; Lin WH; Lien TW; Chen X; Hsu JT; Chao YS; Huang CF; Lyu PC; Hsieh HP; Wu SY
ChemMedChem; 2010 Oct; 5(10):1707-16. PubMed ID: 20734309
[TBL] [Abstract][Full Text] [Related]
10. Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling.
Deng G; Liu Z; Ye F; Luo X; Zhu W; Shen X; Liu H; Jiang H
Eur J Med Chem; 2008 Dec; 43(12):2699-716. PubMed ID: 18329752
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and structure-activity relationship study of novel pyrazole-based heterocycles as potential antitumor agents.
Farag AM; Ali KA; El-Debss TM; Mayhoub AS; Amr AG; Abdel-Hafez NA; Abdulla MM
Eur J Med Chem; 2010 Dec; 45(12):5887-98. PubMed ID: 20950898
[TBL] [Abstract][Full Text] [Related]
12. Rhodanine derivatives as novel peroxisome proliferator-activated receptor gamma agonists.
Liu Q; Zhang YY; Lu HL; Li QY; Zhou CH; Wang MW
Acta Pharmacol Sin; 2007 Dec; 28(12):2033-9. PubMed ID: 18031620
[TBL] [Abstract][Full Text] [Related]
13. The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARgamma: bioassay with molecular modeling simulation.
Ye F; Zhang ZS; Luo HB; Shen JH; Chen KX; Shen X; Jiang HL
Chembiochem; 2006 Jan; 7(1):74-82. PubMed ID: 16317783
[TBL] [Abstract][Full Text] [Related]
14. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
[TBL] [Abstract][Full Text] [Related]
15. A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist.
Chen Q; Chen J; Sun T; Shen J; Shen X; Jiang H
Anal Biochem; 2004 Dec; 335(2):253-9. PubMed ID: 15556564
[TBL] [Abstract][Full Text] [Related]
16. A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: design and synthesis of benzylpyrazole acylsulfonamides.
Rikimaru K; Wakabayashi T; Abe H; Imoto H; Maekawa T; Ujikawa O; Murase K; Matsuo T; Matsumoto M; Nomura C; Tsuge H; Arimura N; Kawakami K; Sakamoto J; Funami M; Mol CD; Snell GP; Bragstad KA; Sang BC; Dougan DR; Tanaka T; Katayama N; Horiguchi Y; Momose Y
Bioorg Med Chem; 2012 Jan; 20(2):714-33. PubMed ID: 22209730
[TBL] [Abstract][Full Text] [Related]
17. Pyrazole derivatives as partial agonists for the nicotinic acid receptor.
van Herk T; Brussee J; van den Nieuwendijk AM; van der Klein PA; IJzerman AP; Stannek C; Burmeister A; Lorenzen A
J Med Chem; 2003 Aug; 46(18):3945-51. PubMed ID: 12930155
[TBL] [Abstract][Full Text] [Related]
18. Identification of a PPARdelta agonist with partial agonistic activity on PPARgamma.
Connors RV; Wang Z; Harrison M; Zhang A; Wanska M; Hiscock S; Fox B; Dore M; Labelle M; Sudom A; Johnstone S; Liu J; Walker NP; Chai A; Siegler K; Li Y; Coward P
Bioorg Med Chem Lett; 2009 Jul; 19(13):3550-4. PubMed ID: 19464171
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-γ modulators.
Naim MJ; Alam O; Alam MJ; Shaquiquzzaman M; Alam MM; Naidu VGM
Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700223. PubMed ID: 29400412
[TBL] [Abstract][Full Text] [Related]
20. Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists.
Marinozzi M; Carotti A; Sansone E; Macchiarulo A; Rosatelli E; Sardella R; Natalini B; Rizzo G; Adorini L; Passeri D; De Franco F; Pruzanski M; Pellicciari R
Bioorg Med Chem; 2012 Jun; 20(11):3429-45. PubMed ID: 22564381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
